Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

Top Fed officials rethink rate cuts as peace talks begin

View original at finance.yahoo.com
Top Fed officials rethink rate cuts as peace talks begin The sooner the Iran War ends, the sooner the Federal Reserve can consider cutting interest rates -- something the central bank and traders had expected at the beginning of the year…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Economic challenges from the Iran War could resolve later this year if supply disruptions in the energy market resolve relatively soon

    60% confidence
  • Jerome Powell should slash interest rates to 1% or lower

    60% confidence
  • The central bank's current wait-and-see approach to interest-rate cuts is appropriate given additional risks to the Fed's dual mandate

    60% confidence
  • The energy developments have increased the risks of higher inflation further out if the energy crisis remains in place for a long period of time or gets worse

    60% confidence
  • Jerome Powell is a moron and is 'Too Late' on rate cuts

    60% confidence
  • The Middle East conflict could lead to a more difficult dynamic in which prices are rising at the same time that the U.S. economy is slowing, and this has begun to play out already

    60% confidence
  • Monetary policymakers would be open to cutting interest rates again later this year if peace in the Middle East was reached in a timely manner

    60% confidence
  • The Iran War is likely to drive up inflation in the near term

    60% confidence
  • Underlying inflation would continue to move toward 2%, leaving him cautious about rate cuts now and more inclined toward cuts to support the labor market later this year when the outlook is more steady

    60% confidence

Data points we hold from this source

Federal Reserve · rate cut forecast1 cuts
Federal Reserve · inflation target2 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com